Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Documenti analoghi

• Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A Literature Review on Pathophysiology and Treatment
  di: Michael Romanos, et al.
  Pubblicazione: (2026)
• A Single Non‐Invasive Test Cut‐Off Should Not Serve Three Distinct Clinical Purposes in Metabolic Dysfunction‐Associated Steatotic Liver Disease and Steatohepatitis
  di: Gong Feng, et al.
  Pubblicazione: (2026)
• Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
  di: Joe Hollinghurst, et al.
  Pubblicazione: (2026)
• Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm
  di: Chan‐Young Jung, et al.
  Pubblicazione: (2026)
• Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study
  di: Jaehyun Bae, et al.
  Pubblicazione: (2026)